I am a Healthcare Professional

These posters, oral presentations, and/or abstracts are provided for medical and scientific purposes only, they may include investigational use or agents that are not approved by health authorities. The information presented is not meant to convey conclusions of safety or effectiveness prior to any regulatory approval from a health authority.

Sanofi does not recommend the use of any products in a manner inconsistent with that described in the full prescribing information. Please refer to the prescribing information in your country of practice for any medicinal products mentioned.

Availability of posters and/or abstracts on this site will conform with conference embargo policies. By selecting “Accept”, you are certifying that you are a Healthcare Professional.

Reject

GBS CIDP 2025 | Sep 11, 2025 - Sep 13, 2025

Neurology

Using cutting-edge technologies, Sanofi scientists are developing targeted, potentially disease-modifying therapies for people living with multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chronic inflammatory demyelinating polyneuropathy (CIDP), and other chronic, debilitating neurological disorders. Our goal is to design best-in-class medicines that slow or halt neurodegeneration, control neuroinflammation, and protect or even repair the nervous system.

Available rooms
1 of 1

  • Chronic Inflammatory Demyelinating Polyneuropathy

    Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, acquired autoimmune disease of the peripheral nerves and nerve roots. The immune-mediated loss of myelin sheaths that occurs in CIDP classically leads to proximal and distal muscle weakness and numbness. Characterized as a relapsing or progressive disease, the disorder ultimately results in disability accumulation. Diagnosis of CIDP is challenging due to its rarity, heterogeneous presentation, and identification by exclusion.